Personalizing Anti-Cancer Treatment from Genetic and Pharmacokinetic Perspective UITNO PDF
Preview Personalizing Anti-Cancer Treatment from Genetic and Pharmacokinetic Perspective UITNO
UITNODIGING voor het bijwonen van de openbare verdediging van het proefschrif Personalizing Ant-Cancer Treatment from Genetc Personalizing Ant-Cancer and Pharmacokinetc Perspectve Treatment from Genetc and Pharmacokinetc Perspectve woensdag 15 februari 2017 13.30 uur Sander Bins Na afoop van de verdediging bent u van harte uitgenodigd voor de recepte Professor Andries Queridozaal Erasmus MC faculteit Onderwijscentrum Wytemaweg 80, Roterdam Sander Bins Ferdinand Bolstraat 29 3583 AP Utrecht Personalizing Anti-Cancer Treatment from Genetic and Pharmacokinetic Perspective Het personaliseren van de behandeling tegen kanker vanuit genetisch en farmacokinetisch oogpunt Sander Bins Personalizing Anti-Cancer Treatment from Genetic and Pharmacokinetic Perspective Het personaliseren van de behandeling tegen kanker vanuit genetisch en farmacokinetisch oogpunt Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.A.P. Pols en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op Woensdag 15 februari 2017 om 13.30 uur Sander Bins geboren te Voorburg Colofon ISBN: 978-94-6299-502-4 Printed by: Ridderprint BV © Sander Bins, 2016 Allrights reserverd. No parts of this book may be reproduced or transmitted, in any form or by any means, without writen permision of the author. P e r d s o n a l i z i n g A n t i - C a n c e r T r e a t m e n t f r o m G e n e t i c a n Pharmacokinetic Perspective Het personaliseren van de behandeling tegen kanker vanuit genetisch en farmacokinetisch oogpunt Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.A.P. Pols en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op Woensdag 15 februari 2017 om 13.30 uur Sander Bins geboren te Voorburg Colofon ISBN: 978-94-6299-502-4 Printed by: Ridderprint BV © Sander Bins, 2016 Allrights reserverd. No parts of this book may be reproduced or transmitted, in any form or by any means, without writen permision of the author. Promotiecommissie Promotoren: Prof.dr. S. Sleijfer Hoe verder men keek, Prof.dr. A.H.J. Mathijssen hoe groter het leek. J.A. Deelder Overige leden: Prof.dr. R.H.N. van Schaik Prof.dr. A.D.R. Huitema Prof.dr. E.E. Voest Promotiecomisie Promotoren: Prof.dr. S. Sleijfer Hoe verder men keek, Prof.dr. A.H.J. Mathijssen hoe groter het leek. J.A. Deelder Overige leden: Prof.dr. R.H.N. van Schaik Prof.dr. A.D.R. Huitema Prof.dr. E.E. Voest Contents Chapter 1 Introduction 9 Chapter 2 Implementation of a multicenter biobanking 17 collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pre- treatment tumor biopsies Oncologist. 2016 Sep 23 [Epub ahead of print] Chapter 3 The time to progression ratio: a new individualized 43 volumetric parameter for the early detection of clinical benefit of targeted therapies Ann. Oncol. 2016;27(8):1638-1643 Chapter 4 Conventional dosing of anticancer agents: precisely 61 wrong or just inaccurate? Clin. Pharmacol. Ther. 2014;95(4):361-364 Chapter 5 Influence of OATP1B1 Function on the Disposition of 69 Sorafenib-β-D-Glucuronide Submitted Chapter 6 Polymorphisms in SLCO1B1 and UGT1A1 are 95 associated with sorafenib-induced toxicity Pharmacogenomics 2016;17(14):1483-1490 Chapter 7 Prospective Analysis in GIST Patients on the Role of 111 Alpha-1 Acid Glycoprotein in Imatinib Exposure Clin Pharmacokinet. 2016 Jul 26 [Epub ahead of print] Chapter 8 Individualized pazopanib dosing: a prospective 125 feasibility study in cancer patients Clin. Cancer Res. 2016;22(23):5738-5746 Chapter 9 Development and clinical validation of an LC-MS/MS 145 method for the quantification of pazopanib in DBS. Bioanalysis. 2016;8(2):123-134 Chapter 10 Discussion 167 Chapter 11 Dutch summary 181 Appendices 187 Contents Chapter 1 Introduction 9 Chapter 2 Implementation of a multicenter biobanking 17 collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pre- treatment tumor biopsies Oncologist. 2016 Sep 23 [Epub ahead of print] Chapter 3 The time to progression ratio: a new individualized 43 volumetric parameter for the early detection of clinical benefit of targeted therapies Ann. Oncol. 2016;27(8):1638-1643 Chapter 4 Conventional dosing of anticancer agents: precisely 61 wrong or just inaccurate? Clin. Pharmacol. Ther. 2014;95(4):361-364 Chapter 5 Influence of OATP1B1 Function on the Disposition of 69 Sorafenib-β-D-Glucuronide Submitted Chapter 6 Polymorphisms in SLCO1B1 and UGT1A1 are 95 associated with sorafenib-induced toxicity Pharmacogenomics 2016;17(14):1483-1490 Chapter 7 Prospective Analysis in GIST Patients on the Role of 111 Alpha-1 Acid Glycoprotein in Imatinib Exposure Clin Pharmacokinet. 2016 Jul 26 [Epub ahead of print] Chapter 8 Individualized pazopanib dosing: a prospective 125 feasibility study in cancer patients Clin. Cancer Res. 2016;22(23):5738-5746 Chapter 9 Development and clinical validation of an LC-MS/MS 145 method for the quantification of pazopanib in DBS. Bioanalysis. 2016;8(2):123-134 Chapter 10 Discussion 167 Chapter 11 Dutch summary 181 Appendices 187 CHAPTER 1 Introduction
The list of books you might like
